Park Jiwon, Park Sang-Min, Ham Dae-Woong, Hong Jae-Young, Kim Ho-Joong, Yeom Jin S
Department of Orthopedic Surgery, Korea University Ansan Hospital, Ansan-si 15355, Republic of Korea.
Spine Center and Department of Orthopedic Surgery, Seoul National University College of Medicine and Seoul National University Bundang Hospital, Seongnam 13620, Republic of Korea.
J Clin Med. 2023 Jun 15;12(12):4069. doi: 10.3390/jcm12124069.
A CaO-SiO-PO-BO bioactive glass-ceramic (BGS-7) spacer provides high mechanical stability, produces a chemical bond to the adjacent endplate, and facilitates fusion after spine surgery. This prospective, randomized, single-blind, non-inferiority trial aimed to evaluate the radiographic outcomes and clinical efficacy of anterior cervical discectomy and fusion (ACDF) using a BGS-7 spacer for treating cervical degenerative disorders. Thirty-six patients underwent ACDF using a BGS-7 spacer (Group N), and 40 patients underwent ACDF using polyetheretherketone (PEEK) cages filled with a mixture of hydroxyapatite (HA) and β-tricalcium phosphate (β-TCP) for the treatment of cervical degenerative disorders. The spinal fusion rate was assessed 12 months postoperatively using three-dimensional computed tomography (CT) and dynamic radiographs. Clinical outcomes included patient-reported outcome measures, visual analog scale scores for neck and arm pain, and scores from the neck disability index (NDI), European Quality of Life-5 Dimensions (EQ-5D), and 12-item Short Form Survey (SF-12v2). All participants were randomly assigned to undergo ACDF using either a BGS-7 spacer or PEEK cage filled with HA and β-TCP. The primary outcome was the fusion rate on CT scan image at 12 months after ACDF surgery based on a per-protocol strategy. Clinical outcomes and adverse events were also assessed. The 12-month fusion rates for the BGS-7 and PEEK groups based on CT scans were 81.8% and 74.4%, respectively, while those based on dynamic radiographs were 78.1% and 73.7%, respectively, with no significant difference between the groups. There were no significant differences in the clinical outcomes between the two groups. Neck pain, arm pain, NDI, EQ-5D, and SF-12v2 scores significantly improved postoperatively, with no significant differences between the groups. No adverse events were observed in either group. In ACDF surgery, the BGS-7 spacer showed similar fusion rates and clinical outcomes as PEEK cages filled with HA and β-TCP.
一种CaO-SiO-PO-BO生物活性玻璃陶瓷(BGS-7)椎间融合器具有较高的机械稳定性,能与相邻终板形成化学键,并有助于脊柱手术后的融合。这项前瞻性、随机、单盲、非劣效性试验旨在评估使用BGS-7椎间融合器进行颈椎前路椎间盘切除融合术(ACDF)治疗颈椎退行性疾病的影像学结果和临床疗效。36例患者使用BGS-7椎间融合器接受ACDF手术(N组),40例患者使用填充有羟基磷灰石(HA)和β-磷酸三钙(β-TCP)混合物的聚醚醚酮(PEEK)椎间融合器接受ACDF手术,以治疗颈椎退行性疾病。术后12个月使用三维计算机断层扫描(CT)和动态X线片评估脊柱融合率。临床结果包括患者报告的结局指标、颈部和手臂疼痛的视觉模拟量表评分,以及颈部功能障碍指数(NDI)、欧洲生活质量五维度(EQ-5D)和12项简明健康调查(SF-12v2)的评分。所有参与者被随机分配接受使用BGS-7椎间融合器或填充有HA和β-TCP的PEEK椎间融合器的ACDF手术。主要结局是基于符合方案策略的ACDF手术后12个月CT扫描图像上的融合率。还评估了临床结果和不良事件。基于CT扫描,BGS-7组和PEEK组的12个月融合率分别为81.8%和74.4%,而基于动态X线片的融合率分别为78.